FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950244511> ?p ?o ?g. }

• W2950244511 endingPage "566" @default.
• W2950244511 startingPage "565" @default.
• W2950244511 abstract "Background: Induction chemotherapy followed by BEAM high dose chemotherapy (HDCT) and autologous peripheral blood stem cell transplant (PBSC transplant) is standard of care for transplant-eligible patients with relapsed or refractory classical Hodgkin lymphoma (rrHL). However, approx. 50% of patients relapse and therefore, this strategy must be improved. Aims: As response to induction therapy is predictive of the outcome after HDCT, this trial aimed at improving the response to induction therapy by adding oral everolimus to time-intensified standard DHAP (Ever-DHAP). Methods: We included patients with histologically confirmed rrHL aged 18–60 years in this phase I/II trial. Dosage of everolimus was pre-determined in the phase I part with 10 mg/day in parallel to DHAP for 14 days within each of two cycles. The phase II part started as a randomized controlled trial comparing 50 patients in the everolimus group to 50 patients in a placebo group. The primary endpoint of the phase II part was the CT-based complete remission (CR-) rate after two cycles of Ever-DHAP. This CR-rate would be expected to be ≥ 40% if adding everolimus was effective. Secondary endpoints of the trial were PET-based CR-rate after two cycles of induction, progression-free and overall survival as well as time to recovery, adverse events, duration of induction therapy, discontinuation rates and rates of successful PBSC collection. The trial was registered at ClinicalTrials.gov with ID NCT01453504. Results: From 7/2014 to 3/2018 we recruited a total of 59 patients in the phase II part. Because of poor recruitment the placebo group was closed in 9/2015 after 9 patients were randomized. Of 50 patients in the everolimus group 2 did not start therapy; 3 additional patients discontinued Ever-DHAP because of toxicity. Nine patients (20%) and 13 patients (28%) needed dose reductions in the first and second cycle of Ever-DHAP, respectively. A delayed recovery >14 days was observed in 2 patients (5%) in cycle 1 and in 6 patients (13%) in cycle 2. CTCAE grade IV toxicities occurred in 39 patients (95%) and 27 patients (75%) in cycle 1 and 2, respectively. All grade IV-toxicities were hematological toxicities. Apheresis needed 1 day in 35 (80%) of the Ever-DHAP patients and 2 days in 8 patients (18%). PBSC collection was successful in 38/42 documented patients receiving Ever-DHAP (91%). After two cycles of therapy we observed a CT-based CR in 12/45 patients of the everolimus group (27%) and in 2/9 patients of the placebo group (22%). A PET-based CR was achieved by 22/39 patients of the everolimus group (56%) and by 2/8 patients of the placebo group (25%). In the everolimus group 2 patients had progressive disease (4%) and 3 died (7%, not related to Ever-DHAP). Final results and additional analyses will be presented. Summary/Conclusion: With a CT-based CR-rate of 27% after two cycles of everolimus plus DHAP (PET-based CR-rate 56%), the trial did not meet the primary endpoint. Adding everolimus to time-intensified DHAP is feasible, however, everolimus plus DHAP failed to show an improved efficacy." @default.
• W2950244511 created "2019-06-27" @default.
• W2950244511 creator A5000359788 @default.
• W2950244511 creator A5008084507 @default.
• W2950244511 creator A5009105040 @default.
• W2950244511 creator A5017098021 @default.
• W2950244511 creator A5021060422 @default.
• W2950244511 creator A5022075377 @default.
• W2950244511 creator A5023596964 @default.
• W2950244511 creator A5039359872 @default.
• W2950244511 creator A5040458257 @default.
• W2950244511 creator A5042447921 @default.
• W2950244511 creator A5042459008 @default.
• W2950244511 creator A5043343452 @default.
• W2950244511 creator A5048023278 @default.
• W2950244511 creator A5053108083 @default.
• W2950244511 creator A5059804319 @default.
• W2950244511 creator A5064079562 @default.
• W2950244511 creator A5065019405 @default.
• W2950244511 creator A5066352955 @default.
• W2950244511 creator A5078010955 @default.
• W2950244511 creator A5080298171 @default.
• W2950244511 creator A5080373266 @default.
• W2950244511 creator A5082045927 @default.
• W2950244511 creator A5082576550 @default.
• W2950244511 date "2019-06-01" @default.
• W2950244511 modified "2023-09-26" @default.
• W2950244511 title "PS1241 CHECKPOINT INHIBITOR TREATMENT BEFORE HAPLOIDENTICAL TRANSPLATATION IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA (HL) PATIENTS IS ASSOCIATED WITH HIGHER PFS WITHOUT INCREASED TOXICITIES" @default.
• W2950244511 doi "https://doi.org/10.1097/01.hs9.0000563244.72263.27" @default.
• W2950244511 hasPublicationYear "2019" @default.
• W2950244511 type Work @default.
• W2950244511 sameAs 2950244511 @default.
• W2950244511 citedByCount "0" @default.
• W2950244511 crossrefType "journal-article" @default.
• W2950244511 hasAuthorship W2950244511A5000359788 @default.
• W2950244511 hasAuthorship W2950244511A5008084507 @default.
• W2950244511 hasAuthorship W2950244511A5009105040 @default.
• W2950244511 hasAuthorship W2950244511A5017098021 @default.
• W2950244511 hasAuthorship W2950244511A5021060422 @default.
• W2950244511 hasAuthorship W2950244511A5022075377 @default.
• W2950244511 hasAuthorship W2950244511A5023596964 @default.
• W2950244511 hasAuthorship W2950244511A5039359872 @default.
• W2950244511 hasAuthorship W2950244511A5040458257 @default.
• W2950244511 hasAuthorship W2950244511A5042447921 @default.
• W2950244511 hasAuthorship W2950244511A5042459008 @default.
• W2950244511 hasAuthorship W2950244511A5043343452 @default.
• W2950244511 hasAuthorship W2950244511A5048023278 @default.
• W2950244511 hasAuthorship W2950244511A5053108083 @default.
• W2950244511 hasAuthorship W2950244511A5059804319 @default.
• W2950244511 hasAuthorship W2950244511A5064079562 @default.
• W2950244511 hasAuthorship W2950244511A5065019405 @default.
• W2950244511 hasAuthorship W2950244511A5066352955 @default.
• W2950244511 hasAuthorship W2950244511A5078010955 @default.
• W2950244511 hasAuthorship W2950244511A5080298171 @default.
• W2950244511 hasAuthorship W2950244511A5080373266 @default.
• W2950244511 hasAuthorship W2950244511A5082045927 @default.
• W2950244511 hasAuthorship W2950244511A5082576550 @default.
• W2950244511 hasBestOaLocation W29502445111 @default.
• W2950244511 hasConcept C121332964 @default.
• W2950244511 hasConcept C126322002 @default.
• W2950244511 hasConcept C141071460 @default.
• W2950244511 hasConcept C142424586 @default.
• W2950244511 hasConcept C143998085 @default.
• W2950244511 hasConcept C181199279 @default.
• W2950244511 hasConcept C185592680 @default.
• W2950244511 hasConcept C197934379 @default.
• W2950244511 hasConcept C203092338 @default.
• W2950244511 hasConcept C2776611710 @default.
• W2950244511 hasConcept C2776694085 @default.
• W2950244511 hasConcept C2778715236 @default.
• W2950244511 hasConcept C2779617269 @default.
• W2950244511 hasConcept C2779699572 @default.
• W2950244511 hasConcept C2780739268 @default.
• W2950244511 hasConcept C31760486 @default.
• W2950244511 hasConcept C535046627 @default.
• W2950244511 hasConcept C55493867 @default.
• W2950244511 hasConcept C71924100 @default.
• W2950244511 hasConcept C87355193 @default.
• W2950244511 hasConceptScore W2950244511C121332964 @default.
• W2950244511 hasConceptScore W2950244511C126322002 @default.
• W2950244511 hasConceptScore W2950244511C141071460 @default.
• W2950244511 hasConceptScore W2950244511C142424586 @default.
• W2950244511 hasConceptScore W2950244511C143998085 @default.
• W2950244511 hasConceptScore W2950244511C181199279 @default.
• W2950244511 hasConceptScore W2950244511C185592680 @default.
• W2950244511 hasConceptScore W2950244511C197934379 @default.
• W2950244511 hasConceptScore W2950244511C203092338 @default.
• W2950244511 hasConceptScore W2950244511C2776611710 @default.
• W2950244511 hasConceptScore W2950244511C2776694085 @default.
• W2950244511 hasConceptScore W2950244511C2778715236 @default.
• W2950244511 hasConceptScore W2950244511C2779617269 @default.
• W2950244511 hasConceptScore W2950244511C2779699572 @default.
• W2950244511 hasConceptScore W2950244511C2780739268 @default.
• W2950244511 hasConceptScore W2950244511C31760486 @default.
• W2950244511 hasConceptScore W2950244511C535046627 @default.
• W2950244511 hasConceptScore W2950244511C55493867 @default.
• W2950244511 hasConceptScore W2950244511C71924100 @default.
• W2950244511 hasConceptScore W2950244511C87355193 @default.

• next